Grace Therapeutics, Inc. (GRCE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Grace Therapeutics, Inc. stock (GRCE) is currently trading at $4.69. Grace Therapeutics, Inc. PS ratio (Price-to-Sales) is 197.75. Analyst consensus price target for GRCE is $11.44. WallStSmart rates GRCE as Sell.
- GRCE PE ratio analysis and historical PE chart
- GRCE PS ratio (Price-to-Sales) history and trend
- GRCE intrinsic value — DCF, Graham Number, EPV models
- GRCE stock price prediction 2025 2026 2027 2028 2029 2030
- GRCE fair value vs current price
- GRCE insider transactions and insider buying
- Is GRCE undervalued or overvalued?
- Grace Therapeutics, Inc. financial analysis — revenue, earnings, cash flow
- GRCE Piotroski F-Score and Altman Z-Score
- GRCE analyst price target and Smart Rating
Grace Therapeutics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Grace Therapeutics, Inc. (GRCE) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Grace Therapeutics, Inc. (GRCE) Key Strengths (1)
Trading at 1.05x book value, attractively priced
Supporting Valuation Data
Grace Therapeutics, Inc. (GRCE) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 197.8x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Grace Therapeutics, Inc. (GRCE) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 8.0/10) while 4 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.05) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (197.75) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -10.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -10.20% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GRCE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GRCE's Price-to-Sales ratio of 197.75x sits near its historical average of 222.46x (9th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 36% below its historical high of 309.24x set in Feb 2026, and 18% above its historical low of 167.24x in Mar 2025. Over the past 12 months, the PS ratio has expanded from ~167.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Grace Therapeutics, Inc. (GRCE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Grace Therapeutics, Inc. operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Grace Therapeutics, Inc..
Bottom Line
Grace Therapeutics, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Grace Therapeutics, Inc.(GRCE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company is headquartered in Princeton, New Jersey.